Filing Details

Accession Number:
0001209191-20-045101
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-05 16:20:47
Reporting Period:
2020-08-03
Accepted Time:
2020-08-05 16:20:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1661567 Michael Parini C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Chief Adm, Leg & Bd Off No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-03 2,330 $86.52 29,168 No 4 M Direct
Common Stock Disposition 2020-08-03 500 $276.98 28,668 No 4 S Direct
Common Stock Disposition 2020-08-03 1,100 $278.13 27,568 No 4 S Direct
Common Stock Disposition 2020-08-03 730 $279.41 26,838 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-08-03 2,330 $0.00 2,330 $86.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,660 2027-02-02 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $276.98 (range $276.60 to $277.39).
  3. Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $278.13 (range $277.73 to $278.58).
  5. Open market sales reported on this line occurred at a weighted average price of $279.41 (range $279.03 to $279.70).
  6. The option vests in 16 quarterly installments from 02/03/2017.